Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma

Published:2020-07-22 Issue:2 Volume:16 Page:52-64
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Krysanov I. S.¹^ORCID,Krysanova V. S.²^ORCID,Alekseev B. Ya.³^ORCID,Ermakova V. Yu.⁴^ORCID,Gameeva E. V.⁵^ORCID

Affiliation:

1. Medical Institute of Continuing Education, Moscow State University of Food Production; Research Center for Clinical and Economic Evaluation and Pharmacoeconomics; N.A. Semashko National Research Institute of Public Health

2. Medical Institute of Continuing Education, Moscow State University of Food Production; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia State Budgetary Institution of the Moscow Region Clinical and Economic Analysis Scientific-Practial Center of the Moscow Region Healthcare Ministry

3. Medical Institute of Continuing Education, Moscow State University of Food Production; P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

4. Medical Institute of Continuing Education, Moscow State University of Food Production; Research Center for Clinical and Economic Evaluation and Pharmacoeconomics; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

5. P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference35 articles.

1. Minimum clinical guidelines of the European Society for Medical Oncology (ESMO). ESMO clinical guidelines for renal cell carcinoma diagnosis, treatment and follow-up. Moscow, 2010. (In Russ.).

2. Ljungberg B., Bensalah K., Bex A. et al. European Association of Urology guidelines on renal cell carcinoma. Translated by Yu. Siromo-lot. Scientific ed.: V.B. Matveev. 2014 [Online version]. Available at: https://uroweb.org/wp-content/uploads/EAU-Guidelines-RCC-2014-Russian-%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8-%D0%BF%D0%BE-%D0%BF%D0%BE%D1%87%D0%B5%D1%87%D0%BD%D0%BE-%D0%BA%D0%BB%D0%B5%D1%82%D0%BE%D1%87%D0%BD%D0%BE%D0%BC%D1%83-%D1%80%D0%B0%D0%BA%D1%83.pdf (last access on 01.18.2020). (In Russ.).

3. Kovacs G., Akhtar M., Beckwith B.J. et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183(2):131—3. DOI: 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G.

4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA A Cancer J Clin 2019;69:7-34. DOI: 10.3322/caac.21551.

5. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):706—20. DOI: https://doi.org/10.1093/annonc/mdz056.